These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 2529129)

  • 1. Regional brain distribution of [18F]GBR 13119, a dopamine uptake inhibitor, in CD-1 and C57BL/6 mice.
    Kilbourn MR; Haka MS; Mulholland GK; Sherman PS; Pisani T
    Eur J Pharmacol; 1989 Jul; 166(2):331-4. PubMed ID: 2529129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo binding of the dopamine uptake inhibitor [18F]GBR 13119 in MPTP-treated C57BL/6 mice.
    Kilbourn MR; Mulholland GK; Sherman PS; Pisani T
    Int J Rad Appl Instrum B; 1991; 18(7):803-6. PubMed ID: 1787091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. H MRS identifies lactate rise in the striatum of MPTP-treated C57BL/6 mice.
    Koga K; Mori A; Ohashi S; Kurihara N; Kitagawa H; Ishikawa M; Mitsumoto Y; Nakai M
    Eur J Neurosci; 2006 Feb; 23(4):1077-81. PubMed ID: 16519673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreases in mouse brain NAD+ and ATP induced by 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP): prevention by the poly(ADP-ribose) polymerase inhibitor, benzamide.
    Cosi C; Marien M
    Brain Res; 1998 Oct; 809(1):58-67. PubMed ID: 9795136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo labelling of the neuronal dopamine uptake complex in the mouse striatum by [3H]GBR 12783.
    Vaugeois JM; Bonnet JJ; Costentin J
    Eur J Pharmacol; 1992 Jan; 210(1):77-84. PubMed ID: 1350989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo binding of [18F]GBR 13119 to the brain dopamine uptake system.
    Kilbourn MR
    Life Sci; 1988; 42(14):1347-53. PubMed ID: 3352457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective alterations of gene expression in mice induced by MPTP.
    Xu Z; Cawthon D; McCastlain KA; Slikker W; Ali SF
    Synapse; 2005 Jan; 55(1):45-51. PubMed ID: 15499605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukine-1beta and interleukine-6 levels in striatum and other brain structures after MPTP treatment: influence of behavioral lateralization.
    Shen YQ; Hebert G; Lin LY; Luo YL; Moze E; Li KS; Neveu PJ
    J Neuroimmunol; 2005 Jan; 158(1-2):14-25. PubMed ID: 15589033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thiophenes as phenyl bio-isosteres: application in radiopharmaceutical design--I. Dopamine uptake antagonists.
    Kilbourn MR
    Int J Rad Appl Instrum B; 1989; 16(7):681-6. PubMed ID: 2613523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice.
    Kilbourn MR; Kuszpit K; Sherman P
    Synapse; 2000 Mar; 35(4):250-5. PubMed ID: 10657034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GBR 13098, a selective dopamine uptake inhibitor; behavioural, biochemical and electrophysiological studies.
    Pileblad E; Engberg G
    Naunyn Schmiedebergs Arch Pharmacol; 1986 Dec; 334(4):383-7. PubMed ID: 2950328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on levels of glutamate and aspartate in the mouse brain.
    Chan P; Di Monte DA; Langston JW
    Brain Res; 1994 Jun; 647(2):249-54. PubMed ID: 7922501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of the ambulation-increasing effect of GBR-12909, a selective dopamine uptake inhibitor, in mice.
    Hirate K; Kuribara H
    Jpn J Pharmacol; 1991 Apr; 55(4):501-11. PubMed ID: 1832199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice.
    Mori A; Ohashi S; Nakai M; Moriizumi T; Mitsumoto Y
    Neurosci Res; 2005 Mar; 51(3):265-74. PubMed ID: 15710490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57BL/6 mice. Comparison with three other strains of mice.
    Sundström E; Strömberg I; Tsutsumi T; Olson L; Jonsson G
    Brain Res; 1987 Mar; 405(1):26-38. PubMed ID: 2882814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biodistribution, dosimetry, metabolism and monkey PET studies of [18F]GBR 13119. Imaging the dopamine uptake system in vivo.
    Kilbourn MR; Carey JE; Koeppe RA; Haka MS; Hutchins GD; Sherman PS; Kuhl DE
    Int J Rad Appl Instrum B; 1989; 16(6):569-76. PubMed ID: 2606712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential vulnerability of dopamine receptors in the mouse brain treated with MPTP.
    Tanji H; Araki T; Nagasawa H; Itoyama Y
    Brain Res; 1999 Apr; 824(2):224-31. PubMed ID: 10196452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dopamine-depleting effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in CD-1 mice are gender-dependent.
    Freyaldenhoven TE; Cadet JL; Ali SF
    Brain Res; 1996 Oct; 735(2):232-8. PubMed ID: 8911661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. l-dopa-induced reversal in striatal glutamate following partial depletion of nigrostriatal dopamine with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Holmer HK; Keyghobadi M; Moore C; Meshul CK
    Neuroscience; 2005; 136(1):333-41. PubMed ID: 16198485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2'-NH(2)-MPTP [1-methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine] depletes serotonin and norepinephrine in rats: a comparison with 2'-CH(3)-MPTP [1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine].
    Unger EL; Mazzola-Pomietto P; Murphy DL; Andrews AM
    J Pharmacol Exp Ther; 2002 Nov; 303(2):527-33. PubMed ID: 12388632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.